Case number IPR2017-00190
Acrux DDS Pty Ltd. v. Kaken Pharmaceutical Co., Ltd. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Apr 28, 2021 | 116 | board | Decision Patent Owner's Motion to Expunge Confidential Information Download |
| Feb 24, 2021 | 115 | patent_own | Patent Owner's Motion to Expunge Download |
| Jan 8, 2021 | 114 | board | Download |
| Nov 12, 2020 | 112 | patent_own | Joint Motion to Terminate Proceeding and Request to Treat Settlement Agreement as Business Confidential Information and be Kept Separate Download |
| Nov 12, 2020 | 113 | patent_own | Patent Owner's Updated Exhibit List as of November 12, 2020 Download |
| Aug 11, 2020 | 111 | petitioner | Petitioner Argentum's Sur-Reply ISO Opposition to Motion to Terminate Download |
| Aug 4, 2020 | 110 | board | Order Granting Sur-Reply for Motion to Terminate Download |
| Aug 4, 2020 | 3003 | board | Ex. 3003 Download |
| Aug 2, 2020 | 108 | patent_own | Reply Brief In Support Of Joint Motion To Terminate Proceeding And Request To Treat Settlement Agreement As Business Confidential Information And Be Kept Separate Download |
| Jul 27, 2020 | 107 | petitioner | Petitioner Argentum's Opposition to Joint Motion to Terminate Proceeding Download |
| Jun 22, 2020 | 106 | board | Conduct of the Proceeding Download |
| Jun 22, 2020 | 3002 | board | Exhibit 3002 Download |
| May 13, 2020 | 105 | Joint Motion to Terminate Proceeding and Request to Treat Settlement Agreement as Business Confidential Information and Be Kept Separate Download | |
| Mar 29, 2019 | 104 | Order Lifting Reissue Stay Download | |
| Mar 29, 2019 | 103 | Order Lifting Reissue Stay Download | |
| Jan 16, 2019 | 102 | Patent Owner's Seventh Updated Mandatory Notices Download | |
| Dec 21, 2018 | 99 | Patent Owner¿¿¿s Unopposed Motion for Pro Hac Vice Admission of Joseph T. Jaros 37 C.F.R. sec. 42.10 Download | |
| Dec 21, 2018 | 101 | Conduct of the Proceeding 37 C.F.R. sec. 42.5 Download | |
| Dec 21, 2018 | 100 | Patent Owner¿¿¿s Unopposed Motion for Pro Hac Vice Admission of William A. Rakoczy 37 C.F.R. sec. 42.10 Download | |
| Dec 10, 2018 | 98 | Notification of Receipt of POP Request Download | |
| Dec 10, 2018 | 3001 | Ex. 3001 Download | |
| Dec 6, 2018 | 97 | Patent Owner's Sixth Updated Mandatory Notices Download | |
| Sep 25, 2018 | 93 | ACRUX'S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF JOSEPH T. JAROS Download | |
| Sep 25, 2018 | 94 | ACRUX'S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF WILLIAM A. RAKOCZY Download | |
| Sep 25, 2018 | 96 | DECLARATION OF JOSEPH T JAROS IN SUPPORT OF MOTION FOR PRO HAC ADMISSION Download | |
| Sep 25, 2018 | 95 | DECLARATION OF JOSEPH T. JAROS IN SUPPORT OF MOTION FOR PRO HAC ADMISSION Download | |
| Sep 25, 2018 | 92 | DECLARATION OF WILLIAM A RAKOCZY IN SUPPORT OF MOTION FOR PRO HAC ADMISSION Download | |
| Sep 19, 2018 | 91 | Decision - 37 C.F.R. 42.10 Download | |
| Sep 18, 2018 | 90 | ACRUX'S UPDATED MANDATORY NOTICES Download | |
| Aug 28, 2018 | 88 | ACRUX'S REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY PURSUANT TO 37 C.F.R. ¿¿ 42.10(b) Download | |
| Aug 28, 2018 | 89 | ACRUX'S UNOPPOSED MOTION TO WITHDRAW COUNSEL AND SUBSTITUTE NEW COUNSEL Download | |
| Aug 14, 2018 | 87 | Patent Owner's Fifth Updated Mandatory Notices Download | |
| Aug 7, 2018 | 86 | Patent Owner's Notice of Appeal Download | |
| Jul 27, 2018 | 2203 | Kaken Exhibit 2203 Download | |
| Jul 27, 2018 | 85 | Patent Owner's Updated Exhibit List Download | |
| Jul 27, 2018 | 84 | Patent Owner's Request for Rehearing Under 37 C.F.R. 42.71(d), and for an Expanded Panel Download | |
| Jul 23, 2018 | 83 | Patent Owner's Motion to Preserve the Record Download | |
| Jun 11, 2018 | 82 | ERRATA Download | |
| Jun 6, 2018 | 80 | Final Written Decision Download | |
| Jun 6, 2018 | 79 | Decision Motions to Seal Download | |
| Jun 6, 2018 | 81 | Decision Motions to Strike and to Exclude Download | |
| Apr 11, 2018 | 78 | Hearing Transcript Download | |
| Jan 12, 2018 | 73 | Trial Order Download | |
| Jan 12, 2018 | 76 | Patent Owner's Reply in Support of its Motion to Exclude Download | |
| Jan 12, 2018 | 75 | PUBLIC VERSION - PETITIONERS¿¿¿ REPLY IN SUPPORT OF THEIR MOTION TO EXCLUDE UNDER 37 C.F.R. ¿¿ 42.64(c) Download | |
| Jan 12, 2018 | 77 | PETITIONERS¿¿¿ MOTION TO SEAL Download | |
| Jan 5, 2018 | 2111 | Kaken Exhibit 2111 Download | |
| Jan 5, 2018 | 65 | PUBLIC VERSION - PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF JOHN C. STAINES, JR. Download | |
| Jan 5, 2018 | 2202 | Kaken Exhibit 2202 Download | |
| Jan 5, 2018 | 68 | PETITIONERS UPDATED EXHIBIT LIST - (as of January 5, 2018) Download | |
| Jan 5, 2018 | 71 | Patent Owner's Updated Exhibit List Download | |
| Jan 5, 2018 | 2112 | Kaken Exhibit 2112 Download | |
| Jan 5, 2018 | 2113 | Kaken Exhibit 2113 Download | |
| Jan 5, 2018 | 66 | PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF DR. KENNETH A. WALTERS Download | |
| Jan 5, 2018 | 63 | PETITIONERS¿¿¿ OPPOSITION TO PATENT OWNER¿¿¿S MOTION TO EXCLUDE UNDER 37 C.F.R. ¿¿ 42.64(c) Download | |
| Jan 5, 2018 | 70 | Patent Owner's Opposition to Petitioners' Motion to Exclude Evidence Submitted by Patent Owner under 37 C.F.R. 42.64(C) (REDACTED VERSION) Download | |
| Jan 5, 2018 | 67 | PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF DR. JEFFREY M. WEINBERG Download | |
| Jan 5, 2018 | 72 | Patent Owner's Motion to Seal Patent Owner's Opposition to Petitioners' Motion to Exclude Evidence Download | |
| Jan 5, 2018 | 62 | PETITIONERS¿¿¿ MOTION TO SEAL Download | |
| Jan 5, 2018 | 1535 | Exhibit 1535(a) - "Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?¿¿¿ P.M. Danzon, International Journal of the Economics of Business, 22(2):245-261 (2015). Download | |
| Jan 5, 2018 | 1671 | Declaration of John C. Staines, Jr. in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 Download | |
| Jan 5, 2018 | 1670 | Declaration of Aydin H. Harston in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 Download | |
| Jan 5, 2018 | 1619 | Exhibit 1619(a) - ¿¿¿Physicians-Pharmaceutical Sales Representatives interactions and Conflict of Interest: Challenges and Solutions,¿¿¿ A.R. Patwardhan, The Journal of Health Care Organization, Provision, and Financing, 53:1-5 (2016) Download | |
| Jan 5, 2018 | 1667 | Prosecution History of U.S. Pat. App. No. 15,405,171 Download | |
| Jan 5, 2018 | 1669 | Declaration of Caitlin M. Wilmot in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 Download | |
| Jan 5, 2018 | 1603 | Exhibit 1603(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2013 Download | |
| Jan 5, 2018 | 1626 | Exhibit 1626(a) - ¿¿¿Copay Programs¿¿¿ Increased Value to Manufacturers is Matched by Rising Criticism,¿¿¿ S. Shelly, Pharmaceutical Commerce, 9(1): 1-32 (January 15, 2014) Download | |
| Jan 5, 2018 | 1543 | Exhibit 1543(a) - ¿¿¿Is Walgreens Valeant¿¿¿s New Philidor?¿¿¿ D. A. Hussar, The Pharmacist Activist, vol. 11, no. 2 (February 2016) Download | |
| Jan 5, 2018 | 1672 | Declaration of Lisa N. Phillips in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 Download | |
| Jan 5, 2018 | 1668 | Declaration of Aydin H. Harston in Support of Supplemental Evidence Served May 30, 2017, with attached exhibits Download | |
| Jan 5, 2018 | 1547 | Exhibit 1547(a) - Citron Research, Valeant: Could this be the Pharmaceutical Enron?, For the Rest of the Story, Click Here Download | |
| Jan 5, 2018 | 1554 | Exhibit 1554(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2016 Download | |
| Jan 5, 2018 | 1604 | Exhibit 1604(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2012 Download | |
| Jan 5, 2018 | 1513 | Exhibit 1513(a) - Tadashi Arika et al., Nishi Nihon Journal of Dermatology, 52 (3): 545-549 (1990) Download | |
| Jan 5, 2018 | 1522 | Exhibit 1522(a) - Theodore Rosen et al., Seminars in Cutaneous Medicine and Surgery: Onychomycosis- Diagnosis, Treatment, and Prevention Strategies (Supp. 3), 35 (3S): S51- S55 (2016) Download | |
| Jan 5, 2018 | 1544 | Download | |
| Jan 5, 2018 | 1553 | Exhibit 1553(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 Download | |
| Jan 5, 2018 | 1588 | Exhibit 1588(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended June 30, 2017 Download | |
| Jan 5, 2018 | 1623 | Download | |
| Dec 22, 2017 | 2118 | Kaken Exhibit 2118 Download | |
| Dec 22, 2017 | 2200 | Kaken Exhibit 2200 Download | |
| Dec 22, 2017 | 53 | PETITIONER'S UPDATED EXHIBIT LIST Download | |
| Dec 22, 2017 | 51 | PUBLIC VERSION - PETITIONERS¿¿¿ MOTION TO EXCLUDE EVIDENCE SUBMITTED BY PATENT OWNER UNDER 37 C.F.R. ¿¿ 42.64(c) Download | |
| Dec 22, 2017 | 56 | Patent Owner's Motion for Observations on the Cross-Examination of Kenneth A. Walters Download | |
| Dec 22, 2017 | 58 | Patent Owner's Motion to Exclude Under 37 C.F.R. 42.64(C) Download | |
| Dec 22, 2017 | 2201 | Kaken Exhibit 2201 Download | |
| Dec 22, 2017 | 54 | PETITIONERS¿¿¿ REQUEST FOR ORAL ARGUMENT PURSUANT TO 37 C.F.R. ¿¿ 42.70(a) Download | |
| Dec 22, 2017 | 61 | Patent Owner's Request for Oral Hearing Download | |
| Dec 22, 2017 | 55 | Patent Owner's Motion for Observations on the Cross-Examination of John C. Staines, Jr. Download | |
| Dec 22, 2017 | 57 | Patent Owner's Motion for Observations on the Cross-Examination of Jeffrey M. Weinberg, M.D. Download | |
| Dec 22, 2017 | 2116 | Kaken Exhibit 2116 (REDACTED VERSION) Download | |
| Dec 22, 2017 | 60 | Patent Owner's Updated Exhibit List Download | |
| Dec 22, 2017 | 2117 | Kaken Exhibit 2117 Download | |
| Dec 22, 2017 | 50 | PETITIONERS¿¿¿ MOTION TO SEAL Download | |
| Dec 22, 2017 | 59 | Patent Owner's Motion to Seal Exhibit 2116 Download | |
| Dec 22, 2017 | 1666 | E-mail string, initiated on August 10, 2017 Download | |
| Dec 13, 2017 | 49 | PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED DURING THE DEPOSITIONS OF KENNETH A. WALTERS, Ph.D. AND JEFFREY M. WEINBERG, M.D. PURSUANT TO 37 C.F.R. ¿¿ 42.64 Download | |
| Dec 6, 2017 | 48 | PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION TO STRIKE Download | |
| Dec 6, 2017 | 47 | PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION TO STRIKE Download | |
| Nov 27, 2017 | 46 | Patent Owner's Motion to Strike Download | |
| Nov 27, 2017 | 45 | PETITIONER¿¿¿S UPDATED NOTICE OF COUNSEL UNDER 37 C.F.R. ¿¿ 42.8 Download | |
| Nov 21, 2017 | 44 | Notice of Deposition of Kenneth A. Walters, Ph.D. Download | |
| Nov 21, 2017 | 43 | Order Conduct of the Proceeding Download | |
| Nov 20, 2017 | 41 | Notice of Deposition of John C. Staines, Jr. Download | |
| Nov 20, 2017 | 42 | Notice of Deposition of Jeffrey M. Weinberg, M.D. Download | |
| Nov 13, 2017 | 40 | COPY of Order Joining IPR2017-01429 with IPR2017-00190 Download | |
| Nov 8, 2017 | 39 | Patent Owner's Objections to Evidence Submitted with Petitioner's Reply Download | |
| Nov 1, 2017 | 1544 | The King¿¿¿s Gambit: Valeant¿¿¿s Big Secret Download | |
| Nov 1, 2017 | 1623 | An Exploratory Study to Improve Sales Operations When Selling Multiple Prescription Drugs Download | |
| Nov 1, 2017 | 1553 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 Download | |
| Nov 1, 2017 | 1522 | Antifungal drugs for onychomycosis: efficacy, safety, and mechanisms of action Download | |
| Nov 1, 2017 | 1588 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended June 30, 2017 Download | |
| Nov 1, 2017 | 1500 | Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy Download | |
| Nov 1, 2017 | 1501 | Onychomycosis Download | |
| Nov 1, 2017 | 1502 | Trends in the management of cutaneous fungal infections Download | |
| Nov 1, 2017 | 1503 | Guidelines for treatment of onychomycosis Download | |
| Nov 1, 2017 | 1504 | Meeting Minutes for IND 77732, Division of Dermatology and Dental Products: Office of Drug Evaluation III Download | |
| Nov 1, 2017 | 1505 | U.S. Pat. No. 5,962,476 to Naito et al Download | |
| Nov 1, 2017 | 1506 | PUBLIC VERSION Deposition Transcript of Dr. Yoshiyuki Tatsumi Download | |
| Nov 1, 2017 | 1507 | PUBLIC VERSION Deposition Transcript of Vincent A. Thomas Download | |
| Nov 1, 2017 | 1508 | Deposition Transcript of Dr. Boni E. Elewski Download | |
| Nov 1, 2017 | 1509 | Download | |
| Nov 1, 2017 | 1510 | Download | |
| Nov 1, 2017 | 1511 | Download | |
| Nov 1, 2017 | 1512 | Dermatologic conditions of the foot Download | |
| Nov 1, 2017 | 1513 | Antibacterial activity of topical antifungal agent in the infected sites- study- skin permeability and absorption to horny materials Download | |
| Nov 1, 2017 | 1514 | Pharmacokinetics of antimycotics with emphasis on local treatment Download | |
| Nov 1, 2017 | 1515 | Download | |
| Nov 1, 2017 | 1516 | Download | |
| Nov 1, 2017 | 1517 | Download | |
| Nov 1, 2017 | 1518 | Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy Download | |
| Nov 1, 2017 | 1519 | Download | |
| Nov 1, 2017 | 1520 | Label for Terbinafine Hydrochloride Cream, 1% Download | |
| Nov 1, 2017 | 1521 | Download | |
| Nov 1, 2017 | 1523 | Kaken Research & Development Division: R&D Pipeline Download | |
| Nov 1, 2017 | 1524 | Leaked Documents Shed Light on the Defunct Pharmacy that Brought Valeant to its Knees Download | |
| Nov 1, 2017 | 1525 | Download | |
| Nov 1, 2017 | 1526 | Valeant Pharmaceuticals International, Inc., Investor Conference Call Presentation, October 26, 2015 Download | |
| Nov 1, 2017 | 1527 | Valeant and Pharmacy More Intertwined than Thought Download | |
| Nov 1, 2017 | 1528 | Valeant Under Criminal Investigation Download | |
| Nov 1, 2017 | 1529 | Thomas Reuters StreetEvents, Edited Transcript, VRX.TO - Q3 2015 Valeant Pharmaceuticals International Inc. Earnings Call Download | |
| Nov 1, 2017 | 1530 | Valeant, Philidor RX, and the Uninformed Attack on Specialty Pharmacy Download | |
| Nov 1, 2017 | 1531 | Drug Makers Sidestep Barriers on Pricing Download | |
| Nov 1, 2017 | 1532 | U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies Download | |
| Nov 1, 2017 | 1533 | Download | |
| Nov 1, 2017 | 1534 | Valeant Plunges on Report U.S. Attorney Pursuing Criminal Charges against the Company Download | |
| Nov 1, 2017 | 1535 | Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive Download | |
| Nov 1, 2017 | 1536 | Download | |
| Nov 1, 2017 | 1537 | Adventures in Prior Authorization Download | |
| Nov 1, 2017 | 1538 | Curing the Prior Authorization Headache Download | |
| Nov 1, 2017 | 1539 | Download | |
| Nov 1, 2017 | 1540 | Download | |
| Nov 1, 2017 | 1541 | Valeant Shares Fall After Sales and Earnings Targets Cut Download | |
| Nov 1, 2017 | 1542 | Suit Alleges Valeant Ran Secret Prescription Refill Scam Download | |
| Nov 1, 2017 | 1543 | Download | |
| Nov 1, 2017 | 1545 | Valeant Slumps Again After Rebutting Critical Report Download | |
| Nov 1, 2017 | 1546 | Valeant Pharmaceuticals Under Investigation by Federal Prosecutors Download | |
| Nov 1, 2017 | 1547 | Valeant: Could this be the Pharmaceutical Enron Download | |
| Nov 1, 2017 | 1548 | Download | |
| Nov 1, 2017 | 1549 | CVS, Express Scripts, UnitedHealth Group Cut Off Philidor, Pharmacy Used by Valeant Download | |
| Nov 1, 2017 | 1550 | Download | |
| Nov 1, 2017 | 1551 | Yahoo Finance, Valeant Pharmaceuticals International, Inc., Stock Price Historical Values (Daily), dated from October 1, 2015 through December 31, 2015 Download | |
| Nov 1, 2017 | 1552 | Valeant to Terminate Relationship with Philidor Download | |
| Nov 1, 2017 | 1554 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2016 Download | |
| Nov 1, 2017 | 1555 | Valeant Under Investigation by SEC Download | |
| Nov 1, 2017 | 1556 | Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Download | |
| Nov 1, 2017 | 1557 | Mike Pearson is on His Way Out of Valeant, Former CFO Refuses to Leave Board Download | |
| Nov 1, 2017 | 1558 | Valeant Sold Some Drugs Twice Download | |
| Nov 1, 2017 | 1559 | Valeant Ex-CEO, Ex-CFO Are a Focus of U.S. Criminal Probe Download | |
| Nov 1, 2017 | 1560 | Two are Charged in Fraud and Kickback Scheme Against Valeant Pharmaceuticals Download | |
| Nov 1, 2017 | 1561 | A Realistic Approach to the Obviousness of Inventions Download | |
| Nov 1, 2017 | 1562 | Download | |
| Nov 1, 2017 | 1563 | How Increased Competition From Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry: a CBO Study Download | |
| Nov 1, 2017 | 1564 | Pharmaceutical Industry Antitrust Handbook Download | |
| Nov 1, 2017 | 1565 | Health Insurance and the Growth in Pharmaceutical Expenditures Download | |
| Nov 1, 2017 | 1566 | 100 Best-Selling, Most Prescribed Branded Drugs through March Download | |
| Nov 1, 2017 | 1567 | The life cycle of a pharmaceutical brand Download | |
| Nov 1, 2017 | 1568 | Prescription Drug Pricing in the Private Sector: a CBO Paper Download | |
| Nov 1, 2017 | 1569 | Thomas Reuters StreetEvents, Edited Transcript, VRX.TO - Q3 2016 Valeant Pharmaceuticals International Inc. Earnings Call Download | |
| Nov 1, 2017 | 1570 | Valeant Pharmaceuticals International, Inc. Q2 2015 Financial Results Presentation, dated July 23, 2015 Download | |
| Nov 1, 2017 | 1571 | Valeant Pharmaceuticals International, Inc. First Quarter 2016 Conference Call Presentation, dated June 7, 2016 Download | |
| Nov 1, 2017 | 1572 | Valeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year 2015 Supplemental Information Presentation, dated April 29, 2016 Download | |
| Nov 1, 2017 | 1573 | Valeant Pharmaceuticals International, Inc. 1Q 2017 Financial Results Conference Call Presentation Download | |
| Nov 1, 2017 | 1574 | Valeant Pharmaceuticals International, Inc. 2Q 17 Financial Results Presentation Download | |
| Nov 1, 2017 | 1575 | Valeant: An Enduring Engine for Growth Download | |
| Nov 1, 2017 | 1576 | Download | |
| Nov 1, 2017 | 1577 | Valeant Pharmaceuticals International, Script Tracker Download | |
| Nov 1, 2017 | 1578 | Valeant Pharmaceuticals International, Inc. Second Quarter 2016 Conference Call Presentation Download | |
| Nov 1, 2017 | 1579 | Valeant Pharmaceuticals International, Inc., Jefferies Autumn 2015 Global Healthcare Conference Download | |
| Nov 1, 2017 | 1580 | Inside the Secret World of Drug Company Rebates Download | |
| Nov 1, 2017 | 1581 | Download | |
| Nov 1, 2017 | 1582 | Download | |
| Nov 1, 2017 | 1583 | Download | |
| Nov 1, 2017 | 1584 | Download | |
| Nov 1, 2017 | 1585 | Download | |
| Nov 1, 2017 | 1586 | Download | |
| Nov 1, 2017 | 1587 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended March 31, 2017 Download | |
| Nov 1, 2017 | 1589 | Product Differentiation, Market Structure, and Competition Download | |
| Nov 1, 2017 | 1590 | Consolidated Financial Results for Fiscal 2016 Download | |
| Nov 1, 2017 | 1591 | Valeant Pharmaceuticals International, Inc. Q3 2015 Financial Results Presentation Download | |
| Nov 1, 2017 | 1592 | Valeant Pharmaceuticals International, Inc. Second Quarter 2014 Financial Results Conference Call Presentation, dated July 31, 2014 Download | |
| Nov 1, 2017 | 1593 | Valeant Pharmaceuticals International, Inc. Presentation, dated February 23, 2015 Download | |
| Nov 1, 2017 | 1594 | Pharmaceutical Super Bowl Ads Fall Flat Download | |
| Nov 1, 2017 | 1595 | Download | |
| Nov 1, 2017 | 1596 | A Healthy Ad Market Download | |
| Nov 1, 2017 | 1597 | Promotional spending for prescription drugs Download | |
| Nov 1, 2017 | 1598 | Valeant Pharmaceuticals (VRX) Q3 2014 Results Earnings Call Transcript Download | |
| Nov 1, 2017 | 1599 | Dow Pharmaceutical Sciences Becomes Wholly Owned Subsidiary as Acquisition by Valeant Pharmaceuticals International is Completed Download | |
| Nov 1, 2017 | 1600 | Valeant Pharmaceuticals International, Inc. (VRX) Q4 2014 Results Earnings Call Transcript, dated February 23, 2015 Download | |
| Nov 1, 2017 | 1601 | Returns on Research and Development for 1990s New Drug Introductions Download | |
| Nov 1, 2017 | 1602 | New Drug Application 203567, Approval Letter from Julie Beitz, MD, Director, Office of Drug Evaluation III, Center for Drug Evaluation and Research to Sean Humphrey, Manager, Regulatory Affairs, Dow Pharmaceutical Sciences, Inc., dated June 6, 2014 Download | |
| Nov 1, 2017 | 1603 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2013 Download | |
| Nov 1, 2017 | 1604 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2012 Download | |
| Nov 1, 2017 | 1605 | Download | |
| Nov 1, 2017 | 1606 | Secondary Considerations of Nonobviousness Analysis: The Use of Objective Indicia Following KSR v. Teleflex, 86 N.Y.U. L. Rev. 2070 Download | |
| Nov 1, 2017 | 1607 | Hold the Valeant Applause Download | |
| Nov 1, 2017 | 1608 | Valeant Pharmaceuticals International, Inc., 2015 J.P. Morgan Healthcare Conference, dated January 13, 2015 Download | |
| Nov 1, 2017 | 1609 | Pharma is the 7th Largest Ad Category in the U.S. at $6.4 billion Last Year Download | |
| Nov 1, 2017 | 1610 | Valeant Pharmaceuticals International, Inc. 2015 Financial Guidance Conference Call Presentation, dated January 8, 2015 Download | |
| Nov 1, 2017 | 1611 | Valeant Pharmaceuticals International, Inc. Fourth Quarter Preliminary Unaudited Financial Results 2015 Conference Call Presentation, dated March 15, 2016 Download | |
| Nov 1, 2017 | 1612 | Valeant Pharmaceuticals International, Inc. First Quarter 2015 Financial Results Conference Call Presentation Download | |
| Nov 1, 2017 | 1613 | Anacor Pharmaceuticals Reports Third Quarter 2015 Financial Results Download | |
| Nov 1, 2017 | 1614 | Anacor Pharmaceuticals, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 Download | |
| Nov 1, 2017 | 1615 | Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising Download | |
| Nov 1, 2017 | 1616 | Direct to Consumer Advertising and Prescription Choice Download | |
| Nov 1, 2017 | 1617 | Bladders, Guts and Feet: The Psychology Behind Anthropomorphic Body Parts Download | |
| Nov 1, 2017 | 1618 | Valeant Pharmaceuticals International, Inc. Third Quarter 2014 Financial Results Conference Call Presentation, dated October 20, 2014 Download | |
| Nov 1, 2017 | 1619 | Physicians-Pharmaceutical Sales Representatives interactions and Conflict of Interest: Challenges and Solutions Download | |
| Nov 1, 2017 | 1620 | Following the Script: How Drug Reps Make Friends and Influence Doctors Download | |
| Nov 1, 2017 | 1621 | The Drug Pushers Download | |
| Nov 1, 2017 | 1622 | Promotion and Market Share in the Proton Pump Inhibitor Market: A Case Study Download | |
| Nov 1, 2017 | 1624 | Physician Awareness of Drug Cost: A Systematic Review Download | |
| Nov 1, 2017 | 1625 | Download | |
| Nov 1, 2017 | 1626 | Download | |
| Nov 1, 2017 | 1627 | CVS Plans to Restrict $1,000 Toenail Fungus Drug Jublia Download | |
| Nov 1, 2017 | 1628 | Download | |
| Nov 1, 2017 | 1629 | A Financial Perspective on the Topical Treatment of Onychomycosis Download | |
| Nov 1, 2017 | 1630 | Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2014 Download | |
| Nov 1, 2017 | 1631 | Ortho Dermatologics RX Access Program Download | |
| Nov 1, 2017 | 1632 | Download | |
| Nov 1, 2017 | 1633 | Valeant, Woes Rising, Backs Away From Boldness to Calm Investors Download | |
| Nov 1, 2017 | 1634 | With Valeant, Things Can Always be Worse, and the Past is Never Buried Download | |
| Nov 1, 2017 | 1635 | Pricing and reimbursement in U.S. pharmaceutical markets Download | |
| Nov 1, 2017 | 1636 | Download | |
| Nov 1, 2017 | 1637 | Prescription drug expenditures in 2000: The upward trend continues Download | |
| Nov 1, 2017 | 1638 | Top 200 Brand-Name Drugs by Retail Sales in 2000 Download | |
| Nov 1, 2017 | 1639 | Top 200 Brand-Name Drugs by Retail Sales in 2001 Download | |
| Nov 1, 2017 | 1640 | Top 200 Brand-Name Drugs by Retail Sales in 2002 Download | |
| Nov 1, 2017 | 1641 | Top 200 Brand-Name Drugs by Retail Sales in 2003 Download | |
| Nov 1, 2017 | 1642 | Top 200 Drugs for 2004 by Sales Download | |
| Nov 1, 2017 | 1643 | Top 200 Drugs for 2005 by Sales Download | |
| Nov 1, 2017 | 1644 | Top 200 Drugs for 2006 by Sales Download | |
| Nov 1, 2017 | 1645 | Top 200 Drugs for 2007 by Sales Download | |
| Nov 1, 2017 | 1646 | Consolidated Financial Results for Fiscal 2015 Download | |
| Nov 1, 2017 | 1647 | Consolidated Financial Results for Fiscal 2015 Download | |
| Nov 1, 2017 | 1648 | onsolidated Financial Results for Fiscal 2015 (Reference Data of Financial Statements for the 3Q of Fiscal 2015) Download | |
| Nov 1, 2017 | 1649 | Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements Fiscal 2016 1st Quarter) Download | |
| Nov 1, 2017 | 1650 | Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements for the 2Q of Fiscal 2016), Download | |
| Nov 1, 2017 | 1651 | Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements for the 3Q of Fiscal 2016 Download | |
| Nov 1, 2017 | 1652 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Ciclopirox Download | |
| Nov 1, 2017 | 1653 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Efinaconazole Download | |
| Nov 1, 2017 | 1654 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Fluconazole Download | |
| Nov 1, 2017 | 1655 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Itraconazole Download | |
| Nov 1, 2017 | 1656 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Tavaborole, Download | |
| Nov 1, 2017 | 1657 | Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Terbinafine Download | |
| Nov 1, 2017 | 1658 | Download | |
| Nov 1, 2017 | 1659 | Valeant Pharmaceuticals International, Inc. (VRX) Q2 2014 Results Earnings Call Transcript, dated July 31, 2014, Download | |
| Nov 1, 2017 | 1660 | Download | |
| Nov 1, 2017 | 1661 | Kaken Exhibit 2100, Evidentiary Declaration of Edward Shupenus Download | |
| Nov 1, 2017 | 1662 | Kaken Exhibit 2106, Evidentiary Declaration of Vincent A. Thomas, CPA, CVA, CFF, ABV Download | |
| Nov 1, 2017 | 1664 | Kaken Exhibit 2114, Evidentiary Declaration of Motonori Miyakawa Download | |
| Nov 1, 2017 | 1665 | Kaken Exhibit 2115, Certificate of Translation for the Evidentiary Declaration of Motonori Miyakawa Download | |
| Nov 1, 2017 | 36 | Download | |
| Nov 1, 2017 | 37 | Petitioners Reply to Patent Owners Response Download | |
| Nov 1, 2017 | 38 | PETITIONERS UPDATED EXHIBIT LIST Download | |
| Sep 27, 2017 | 34 | Patent Owners Motion for Pro Hac Vice Admission of Barbara R. Rudolph, Ph.D., and Petitioners Motion for Pro Hac Vice Admission of Lisa N. Phillips 37 C.F.R. sec 42.10 Download | |
| Sep 27, 2017 | 35 | Notice of Deposition of B. E. Elewski Download | |
| Sep 26, 2017 | 32 | NOTICE OF DEPOSITION OF YOSHIYUKI TATSUMI, PH.D Download | |
| Sep 26, 2017 | 33 | NOTICE OF DEPOSITION OF VINCENT A THOMAS Download | |
| Aug 31, 2017 | 31 | Order - Stay of Reissue Application No. 15/405,171 Download | |
| Aug 23, 2017 | 29 | Petitioners' Unopposed Motion For Hac Vice Admission of Lisa N. Phillips Download | |
| Aug 23, 2017 | 30 | Declaration of Lisa N. Phillips Download | |
| Aug 8, 2017 | 28 | PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED WITH PATENT OWNER¿¿¿S RESPONSE PURSUANT TO 37 C.F.R. ¿¿ 42.64(b)(1) Download | |
| Aug 1, 2017 | 2079 | Kaken Exhibit 2079 Download | |
| Aug 1, 2017 | 2091 | Kaken Exhibit 2091 Download | |
| Aug 1, 2017 | 27 | Patent Owner's Response Download | |
| Aug 1, 2017 | 2089 | Kaken Exhibit 2089 Download | |
| Aug 1, 2017 | 2077 | Kaken Exhibit 2077 Download | |
| Aug 1, 2017 | 2097 | Kaken Exhibit 2097 Download | |
| Aug 1, 2017 | 2085 | Kaken Exhibit 2085 Download | |
| Aug 1, 2017 | 2092 | Kaken Exhibit 2092 Download | |
| Aug 1, 2017 | 2086 | Kaken Exhibit 2086 Download | |
| Aug 1, 2017 | 2082 | Kaken Exhibit 2082 Download | |
| Aug 1, 2017 | 2084 | Kaken Exhibit 2084 Download | |
| Aug 1, 2017 | 2073 | Kaken Exhibit 2073 Download | |
| Aug 1, 2017 | 2078 | Kaken Exhibit 2078 Download | |
| Aug 1, 2017 | 26 | Patent Owner's Updated Exhibit List Download | |
| Aug 1, 2017 | 2096 | Kaken Exhibit 2096 Download | |
| Aug 1, 2017 | 2087 | Kaken Exhibit 2087 Download | |
| Aug 1, 2017 | 2090 | Kaken Exhibit 2090 Download | |
| Aug 1, 2017 | 2088 | Kaken Exhibit 2088 Download | |
| Aug 1, 2017 | 2075 | Kaken Exhibit 2075 Download | |
| Aug 1, 2017 | 2080 | Kaken Exhibit 2080 Download | |
| Aug 1, 2017 | 2083 | Kaken Exhibit 2083 Download | |
| Aug 1, 2017 | 2081 | Kaken Exhibit 2081 Download | |
| Aug 1, 2017 | 2074 | Kaken Exhibit 2074 Download | |
| Aug 1, 2017 | 2076 | Kaken Exhibit 2076 Download | |
| Aug 1, 2017 | 25 | Patent Owners' Motion to Seal Exhibits 2093-2095, 2098, and 2099 Download | |
| Aug 1, 2017 | 2060 | Kaken Exhibit 2060 Download | |
| Aug 1, 2017 | 2072 | Kaken Exhibit 2072 Download | |
| Aug 1, 2017 | 2030 | Kaken Exhibit 2030 Download | |
| Aug 1, 2017 | 2048 | Kaken Exhibit 2048 Download | |
| Aug 1, 2017 | 2071 | Kaken Exhibit 2071 Download | |
| Aug 1, 2017 | 2055 | Kaken Exhibit 2055 Download | |
| Aug 1, 2017 | 2050 | Kaken Exhibit 2050 Download | |
| Aug 1, 2017 | 2035 | Kaken Exhibit 2035 Download | |
| Aug 1, 2017 | 2058 | Kaken Exhibit 2058 Download | |
| Aug 1, 2017 | 2054 | Kaken Exhibit 2054 Download | |
| Aug 1, 2017 | 2028 | Kaken Exhibit 2028 Download | |
| Aug 1, 2017 | 2038 | Kaken Exhibit 2038 Download | |
| Aug 1, 2017 | 2069 | Kaken Exhibit 2069 Download | |
| Aug 1, 2017 | 2066 | Kaken Exhibit 2066 Download | |
| Aug 1, 2017 | 2029 | Kaken Exhibit 2029 Download | |
| Aug 1, 2017 | 2059 | Kaken Exhibit 2059 Download | |
| Aug 1, 2017 | 2067 | Kaken Exhibit 2067 Download | |
| Aug 1, 2017 | 2070 | Kaken Exhibit 2070 Download | |
| Aug 1, 2017 | 2051 | Kaken Exhibit 2051 Download | |
| Aug 1, 2017 | 2025 | Kaken Exhibit 2025 Download | |
| Aug 1, 2017 | 2052 | Kaken Exhibit 2052 Download | |
| Aug 1, 2017 | 2047 | Kaken Exhibit 2047 Download | |
| Aug 1, 2017 | 2053 | Kaken Exhibit 2053 Download | |
| Aug 1, 2017 | 2026 | Kaken Exhibit 2026 Download | |
| Aug 1, 2017 | 2068 | Kaken Exhibit 2068 Download | |
| Aug 1, 2017 | 2043 | Kaken Exhibit 2043 Download | |
| Aug 1, 2017 | 2032 | Kaken Exhibit 2032 Download | |
| Aug 1, 2017 | 2064 | Kaken Exhibit 2064 Download | |
| Aug 1, 2017 | 2039 | Kaken Exhibit 2039 Download | |
| Aug 1, 2017 | 2042 | Kaken Exhibit 2042 Download | |
| Aug 1, 2017 | 2034 | Kaken Exhibit 2034 Download | |
| Aug 1, 2017 | 2044 | Kaken Exhibit 2044 Download | |
| Aug 1, 2017 | 2062 | Kaken Exhibit 2062 Download | |
| Aug 1, 2017 | 2065 | Kaken Exhibit 2065 Download | |
| Aug 1, 2017 | 2046 | Kaken Exhibit 2046 Download | |
| Aug 1, 2017 | 2027 | Kaken Exhibit 2027 Download | |
| Aug 1, 2017 | 2057 | Kaken Exhibit 2057 Download | |
| Aug 1, 2017 | 2036 | Kaken Exhibit 2036 Download | |
| Aug 1, 2017 | 2056 | Kaken Exhibit 2056 Download | |
| Aug 1, 2017 | 2037 | Kaken Exhibit 2037 Download | |
| Aug 1, 2017 | 2040 | Kaken Exhibit 2040 Download | |
| Aug 1, 2017 | 2031 | Kaken Exhibit 2031 Download | |
| Aug 1, 2017 | 2045 | Kaken Exhibit 2045 Download | |
| Aug 1, 2017 | 2033 | Kaken Exhibit 2033 Download | |
| Aug 1, 2017 | 2041 | Kaken Exhibit 2041 Download | |
| Aug 1, 2017 | 2049 | Kaken Exhibit 2049 Download | |
| Aug 1, 2017 | 2024 | Kaken Exhibit 2024 Download | |
| Aug 1, 2017 | 2063 | Kaken Exhibit 2063 Download | |
| Jul 18, 2017 | 24 | Patent Owner's Updated Exhibit List Download | |
| Jul 18, 2017 | 23 | Patent Owner's Unopposed Motion For Pro Hac Vice Admission of Barbara R. Rudolph, Ph.D. Download | |
| Jul 18, 2017 | 2023 | Kaken Exhibit 2023 Download | |
| Jul 8, 2017 | 22 | PETITIONERS¿¿¿ REPLY TO PATENT OWNERS¿¿¿ OPPOSITION TO PETITIONERS¿¿¿ MOTION TO STAY REISSUE PROCEEDING Download | |
| Jul 3, 2017 | 21 | Patent Owner's Opposition to Petitioner's Motion to Stay Reissue Proceeding Download | |
| Jun 29, 2017 | 20 | Notice of Deposition of Kenneth A. Walters, Ph.D. Download | |
| Jun 23, 2017 | 19 | Petitioners' Motion to Stay Related Reissue Proceedings Download | |
| Jun 23, 2017 | 1047 | Reissue Application No. 15/405,171, Preliminary Amendment and Remarks, dated 1/12/2017 Download | |
| Jun 23, 2017 | 18 | Patent Owner's Fourth Updated Mandatory Notices Download | |
| Jun 16, 2017 | 17 | Petitioner's Submission of Transcript of June 13, 2017 Conference Call Download | |
| Jun 14, 2017 | 16 | ORDER Conduct of the Proceeding Download | |
| May 15, 2017 | 15 | Patent Owner's Objections to Evidence Download | |
| May 15, 2017 | 14 | PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED WITH PATENT OWNER¿¿¿S PRELIMINARY RESPONSE PURSUANT TO 37 C.F.R. ¿¿ 42.64(b)(1) Download | |
| May 1, 2017 | 12 | DECISION - Institution of Inter Partes Review Download | |
| May 1, 2017 | 13 | SCHEDULING ORDER Download | |
| Mar 1, 2017 | 11 | Conduct of the Proceeding Download | |
| Feb 24, 2017 | 9 | Patent Owner's Updated Mandatory Notices Download | |
| Feb 24, 2017 | 10 | Petitioners Submission of Transcript of February 21, 2017 Conference Call Download | |
| Feb 2, 2017 | 8 | Patent Owner's Preliminary Response Download | |
| Feb 2, 2017 | 7 | Patent Owner's Updated Mandatory Notices Download | |
| Feb 2, 2017 | 2019 | Kaken Exhibit 2019 Download | |
| Feb 2, 2017 | 2009 | Kaken Exhibit 2009 Download | |
| Feb 2, 2017 | 2013 | Kaken Exhibit 2013 Download | |
| Feb 2, 2017 | 2006 | Kaken Exhibit 2006 Download | |
| Feb 2, 2017 | 2017 | Kaken Exhibit 2017 Download | |
| Feb 2, 2017 | 2010 | Kaken Exhibit 2010 Download | |
| Feb 2, 2017 | 2016 | Kaken Exhibit 2016 Download | |
| Feb 2, 2017 | 2008 | Kaken Exhibit 2008 Download | |
| Feb 2, 2017 | 2014 | Kaken Exhibit 2014 Download | |
| Feb 2, 2017 | 2004 | Kaken Exhibit 2004 Download | |
| Feb 2, 2017 | 2020 | Kaken Exhibit 2020 Download | |
| Feb 2, 2017 | 2007 | Kaken Exhibit 2007 Download | |
| Feb 2, 2017 | 2001 | Kaken Exhibit 2001 Download | |
| Feb 2, 2017 | 2005 | Kaken Exhibit 2005 Download | |
| Feb 2, 2017 | 2011 | Kaken Exhibit 2011 Download | |
| Feb 2, 2017 | 2022 | Kaken Exhibit 2022 Download | |
| Feb 2, 2017 | 2018 | Kaken Exhibit 2018 Download | |
| Feb 2, 2017 | 2015 | Kaken Exhibit 2015 Download | |
| Feb 2, 2017 | 2021 | Kaken Exhibit 2021 Download | |
| Feb 2, 2017 | 2003 | Kaken Exhibit 2003 Download | |
| Feb 2, 2017 | 2002 | Kaken Exhibit 2002 Download | |
| Feb 2, 2017 | 2012 | Kaken Exhibit 2012 Download | |
| Dec 27, 2016 | 6 | Patent Owner's Updated Mandatory Notices Download | |
| Dec 12, 2016 | 5 | Patent Owner's Power of Attorney Download | |
| Dec 12, 2016 | 4 | Patent Owner's Mandatory Notices Download | |
| Nov 16, 2016 | 3 | Notice of Accord Filing Date Download | |
| Nov 2, 2016 | 1015 | Kaken Abstracts Download | |
| Nov 2, 2016 | 1045 | Acrux DDS Pty Ltd. Corporate Website Download | |
| Nov 2, 2016 | 1008 | U.S. Pat. No. 5,716,969 Download | |
| Nov 2, 2016 | 1010 | Publication of PCT/JP00/04617 Download | |
| Nov 2, 2016 | 1003 | Press Release Download | |
| Nov 2, 2016 | 1032 | Aly, R., J. Am. Acad. Dermatol., 31:S21¿¿¿S25 (1994) Download | |
| Nov 2, 2016 | 1034 | J. of the American Academy of Dermatology, 35:3(2): S26-S30 (1996) Download | |
| Nov 2, 2016 | 1039 | Walters, K.A., J Invest Dermatol, 76: 76-79 (1981) Download | |
| Nov 2, 2016 | 2 | Power of Attorney Download | |
| Nov 2, 2016 | 1016 | Stuttgen, G. and Bauer, E., Mycoses, 25(2): 74-80 (1992) Download | |
| Nov 2, 2016 | 1011 | Certified English Translation of Japanese Pat. App. Pub. No. 10- 226639 Download | |
| Nov 2, 2016 | 1036 | Buck, D.S. et al., The Journal of Family Practice, 38(6): 601-605 (1994) Download | |
| Nov 2, 2016 | 1005 | Declaration of Kenneth Walters Download | |
| Nov 2, 2016 | 1002 | Certified English Translation of Japanese Pat. App. No. 11/214369 Download | |
| Nov 2, 2016 | 1042 | Walters, K.A., J Pharm Pharmacol, 37: 771-775 (1985) Download | |
| Nov 2, 2016 | 1038 | Spruit, D., J Invest Dermatol, 56(5): 359-361 (1971) Download | |
| Nov 2, 2016 | 1006 | Prosecution History of U.S. Pat. No. 7,214,506 Download | |
| Nov 2, 2016 | 1004 | Orange Book Excerpt for Valeant¿¿¿s Jublia Download | |
| Nov 2, 2016 | 1029 | Hay, R.J., Journal of Antimicrobial Chemotherapy 20: 1-5 (1987) Download | |
| Nov 2, 2016 | 1046 | Acrux DDS Pty Ltd. Corporate Website Download | |
| Nov 2, 2016 | 1031 | Summerbell, R.C., Dermatology, 194 (Supp. 1): 32-36 (1997) Download | |
| Nov 2, 2016 | 1013 | U.S. Pat. No. 5,391,367 Download | |
| Nov 2, 2016 | 1007 | U.S. Pat. No. 5,620,994 Download | |
| Nov 2, 2016 | 1044 | Declaration of Jeff Karr Download | |
| Nov 2, 2016 | 1 | PETITION to Institute an Inter Partes Review of U.S. Patent No. 7,214,506 Download | |
| Nov 2, 2016 | 1025 | Heine, C. AdWeek. (Jan. 27, 2015) Download | |
| Nov 2, 2016 | 1012 | Ogura, H. et al., Chem. Pharm. Bull, 47(10) 1417-1425 (1999) Download | |
| Nov 2, 2016 | 1040 | Walters, K.A., J Pharm Pharmacol 35: 28-33 (1983) Download | |
| Nov 2, 2016 | 1043 | Jublia Package Insert Download | |
| Nov 2, 2016 | 1035 | Vanderdonckt, J., et al., Mykosen, 19(7):251-256 (1975) Download | |
| Nov 2, 2016 | 1019 | van Hoogdalem, E.J. et al., Eur J Pharm Sci 5: 119-127 (1997) Download | |
| Nov 2, 2016 | 1009 | Comparison between the Priority Document Download | |
| Nov 2, 2016 | 1041 | Walters, K.A., J Pharm Pharmacol, 37: 498-499 (1985) Download | |
| Nov 2, 2016 | 1037 | Haria, M. and Bryson, H.M., Drugs, 49(1): 103-120 (1995) Download | |
| Nov 2, 2016 | 1023 | Mertin, D., Journal of Pharmacy and Pharmacology, 49(9): 866-872 (1997) Download | |
| Nov 2, 2016 | 1017 | Ceschin-Roques C.G., et al., Skin Pharmacol, 4: 89-94 (1991) Download | |
| Nov 2, 2016 | 1018 | Franz, T.J., Dermatol, 184(Suppl 1): 18-20 (1992) Download | |
| Nov 2, 2016 | 1030 | J. of the European Academy of Dermatology and Venereology 4 (Supp. 1)(1995) Download | |
| Nov 2, 2016 | 1027 | Burch, G.E., Arch Derm Syphilol 53: 39-41 (1946) Download | |
| Nov 2, 2016 | 1028 | Baden H.P., et al., Biochim Biophys Acta 322:269¿¿¿278 (1973) Download | |
| Nov 2, 2016 | 1024 | Kobayashi Y. et al., Chem Pharm Bull 46: 1797- 1802 (1998) Download | |
| Nov 2, 2016 | 1021 | Mertin, D., Journal of Pharmacy and Pharmacology, 49(1): 30-34 (1997) Download | |
| Nov 2, 2016 | 1001 | U.S. Pat. No. 7,214,506 Download | |
| Nov 2, 2016 | 1026 | Niewerth, M., Drugs 58(2):283-296 (1999) Download | |
| Nov 2, 2016 | 1020 | Quintanar- Guerrero, D. et al., Drug Dev Ind Pharm, 24: 685-690 (1998) Download | |
| Nov 2, 2016 | 1033 | J. of the American Academy of Dermatology, 40 (Suppl):S21¿¿¿6 (1999) Download | |
| Nov 2, 2016 | 1014 | Hay, R.J., et al., Clinical and Experimental Dermatology, 10:111-115 (1985) Download | |
| Nov 2, 2016 | 1022 | Mertin, D., Journal of Pharmacy and Pharmacology, 49(3): 241-245 (1997) Download |
